Can the nephron be spared?
The search continues for the best role for mTOR inhibitor drugs in renal transplantation-principally to avoid or minimize the nephrotoxicity of the CNI class of immunosuppressive agents. The Spare the Nephron Trial describes the popular approach of early conversion from a CNI to the mTOR agent sirolimus for patients maintained on mycophenolate mofetil and steroids. At 1-2 years the glomerular filtration rate (GFR) was superior for the sirolimus group, with a loss of tolerability for about 20%.